Abiomed Inc.

ABMD

$293.77

-11.8% last 12 months

Market Cap

$13.3 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$219.85 - $379.30

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

97.68x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $13.3 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $12.6 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $0.00 (0.0%)
1 Year Return Profit or loss of share price change plus dividend yield. -11.8%
52-Week High Highest share price in the last 52 weeks. $379.30
52-Week Low Lowest share price in the last 52 weeks. $219.85
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 1.54
Outstanding Shares The number of shares the company has issued and are held by stockholders. 45.6 Million
Avg 30 Day Volume The number of shares traded in the last 30 days. 260 Thousand

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 97.68
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. 1600.93
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. $2.98
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 13.35
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 9.18
Enterprise Value to Revenue Enterprise value divided by revenue 12.19
Enterprise Value to EBIT Enterprise Value divided by EBIT 48.99
Total Debt to Enterprise Value Total debt divided by enterprise value 0.0
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 0.0

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $1.03 Billion
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $844 Million
EBIT Earnings before tax and interest payments. $257 Million
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. $137 Million
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. 13.23%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. +6.1%
Return on Equity Equity divided by market cap. 9.08%
Return on Assets Indicates a company's profitability in relation to its total assets. 8.16%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. 16.72%

Insider trades

No purchases

3,135.0 shares sold (3 transactions)

No purchases

13,903.0 shares sold (7 transactions)

No purchases

1,141.0 shares sold (3 transactions)

No purchases

No sells

Q4 2021 Q1 2022 Q2 2022 Q3 2022

About Abiomed Inc.

CEO: Michael Minogue

Employees: 1,371

Industry: Surgical and Medical Instrument Manufacturing

Abiomed is a publicly-traded medical devices company that develops and manufactures the circulatory support device Impella, the world’s smallest heart pump. The company is headquartered in Danvers, Massachusetts and has three additional offices, two in Germany in the cities of Berlin and Aachen, and another in Tokyo, Japan. Michael R. Minogue is Chairman, CEO & President of the company, with Dr. Thorsten Siess as Chief Technology Officer, Dr. Chuck Simonton as Chief Medical Officer and Dr. David M. Weber as Chief Operating Officer. According to Bloomberg, the company "engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients". As of 2019, the company had secured five FDA approvals and 715 patents with 622 pending. For fiscal year 2019, Abiomed reported $769.4 million in revenue and reported diluted earnings per share was $5.61 for the year. Abiomed was founded in Danvers, Massachusetts by David M. Lederman in 1981 as Applied Biomedical Corporation. That year, the company commenced the development of an artificial heart. Funded by federal research grants, Lederman partnered with The Texas Heart Institute to develop the AbioCor, a grapefruit-sized electromagnetic device with an internal battery that completely replaces the heart without wires or tubes passing through the skin. In July 2001, AbioCor became the first artificial heart successfully implanted in a patient, where it pumped more than 20 million times. Fourteen of the AbioCor devices were implanted, during clinical trials from 2001 to 2004, with the longest-living recipient surviving 512 days. The AbioCor won FDA approval in 2006 for patients who are near death and do not qualify for a heart transplant.

Similar stocks

Teleflex Incorporated
Teleflex Incorporated
Boston Scientific Corp.
Boston Scientific Corp.
Stereotaxis Inc
Stereotaxis Inc
Atricure Inc
Atricure Inc

News